Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,409 matching trials from the live ClinicalTrials.gov search.
Conditions
Parkinson Disease, Anxiety
Interventions
Focused breathing
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Parkinson Disease Psychosis
Interventions
SEP-363856, Placebo capsule
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 105 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
24
States / cities
Fresno, California • Los Angeles, California • Riverside, California + 19 more
Completed Phase 4 Interventional Results available

Lundbeck TOMs Orthostatic Hypotension

NCT04510922
Conditions
Orthostatic Hypotension, Idiopathic Parkinson Disease
Interventions
Droxidopa 100 MG [Northera]
Drug
Lead sponsor
Alberto Espay, MD, MSc
Other
Eligibility
30 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Parkinson's Disease (PD)
Interventions
Optimized antiparkinsonian treatment, Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy ambulatory infusion pump, Percutaneous endoscopic gastrostomy tube, Jejunal extension tube
Drug · Device
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Port Charlotte, Florida • Round Rock, Texas
Conditions
Parkinson's Disease
Interventions
ADX48621, Placebo
Drug
Lead sponsor
Addex Pharma S.A.
Industry
Eligibility
30 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 10 more
Conditions
Dementia With Lewy Bodies, REM Sleep Behavior Disorder, Parkinson's Disease Dementia
Interventions
Nelotanserin, Placebo
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 20 more
Conditions
Parkinson's Disease
Interventions
EMST - Active Treatment, sham EMST
Device
Lead sponsor
University of Florida
Other
Eligibility
35 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Neurodegenerative Disease, Weight Loss, Amyotrophic Lateral Sclerosis, Parkinson's Disease, Huntington's Disease, Cachexia
Interventions
In-Person Nutritional Counseling by a Registered Dietitian, Nutritional counseling using an e-Health Application
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Parkinson Disease
Interventions
Digital Speech Application
Device
Lead sponsor
Northwestern University
Other
Eligibility
30 Years and older
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Idiopathic Parkinson's Disease
Interventions
IPX054 200 mg, IPX054 250 mg, CD-LD IR, CD-LD CR, IPX054 200 mg Placebo, IPX054 250 mg Placebo, CD-LD IR Placebo, CD-LD CR Placebo
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Bingham Farms, Michigan • Portland, Oregon
Terminated Not applicable Interventional Accepts healthy volunteers

The Effect of tDCS on Subcortical Brain Functioning

NCT01602276
Conditions
Brain Damage, Chronic
Interventions
Transcranial Direct Current Stimulation (tDCS)
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 79 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Recruiting Not applicable Interventional

Aim 3 Particle Swarm Optimization PIGD

NCT05934747
Conditions
Parkinson's Disease and Parkinsonism
Interventions
DBS
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Parkinson's Disease
Interventions
Pimavanserin, Placebo, Quetiapine
Drug · Other
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 13 more
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Brain Health Registry: An Online Registry to Identify and Assess Subjects for Brain Research

NCT02402426
Conditions
Healthy, Neurodegenerative Disease
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2030
U.S. locations
1
States / cities
San Francisco, California
Conditions
Parkinson Disease, Dysphagia
Interventions
Cough Skill Training - with Variable Practice
Behavioral
Lead sponsor
Teachers College, Columbia University
Other
Eligibility
40 Years to 90 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Parkinson Disease
Interventions
[18F]MK-9470
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Parkinson Disease, Cerebrospinal Fluid
Interventions
N-Acetylcysteine, Lumbar Puncture, Fluoroscopy
Drug · Procedure · Radiation
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Terminated Not applicable Interventional Results available

SHARPEN - Parkinson's Disease Dementia

NCT05987540
Conditions
Parkinson Disease Dementia
Interventions
Non-invasive brainstem stimulation
Device
Lead sponsor
Scion NeuroStim
Industry
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Boca Raton, Florida • Kansas City, Kansas
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
40 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 2 Interventional Results available

Nilotinib in Parkinson's Disease

NCT03205488
Conditions
Parkinson Disease
Interventions
Cohort 1:Nilotinib Oral Capsules (150mg or 300mg), Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1), Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 79 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
24
States / cities
Birmingham, Alabama • Sun City, Arizona • Sacramento, California + 21 more
Conditions
Parkinson's Disease, Tremor, Dystonia
Interventions
Alteration of DBS stimulator settings
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
PARKINSON DISEASE (Disorder)
Interventions
High Intensity Resistance Exercise
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Aurora, Colorado
Completed Phase 3 Interventional Results available

Efficacy of Isradipine in Early Parkinson Disease

NCT02168842
Conditions
Parkinson Disease
Interventions
Isradipine, Placebo (for Isradipine)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
47
States / cities
Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 40 more
Conditions
Parkinson's Disease
Interventions
Mindfulness Based Stress Reduction, Psychoeducational Supportive Care
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
San Diego, California